Follow-up of Patients with Chronic Pulmonary Histoplasmosis Treated with Amphotericin B

Baum, Gerald L.; Larkin, John C.; Sutliff, W. D.

doi:10.1378/chest.58.6.562

Cited by 23 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown amphotericin B to be effective in 59%-100% of cases [6][7][8][9][10][11][12][13][14] (table 3). Ketoconazole and itraconazole are effective in 75%-85% of case patients, but their use is also complicated by high relapse rates [11][12][13].…”

Section: Chronic Pulmonary Histoplasmosismentioning

confidence: 99%

Practice Guidelines for the Management of Patients with Histoplasmosis

Wheat

Sarosi

McKinsey

et al. 2000

Clinical Infectious Diseases

346

196

View full text Add to dashboard Cite

show abstract

Section: Chronic Pulmonary Histoplasmosismentioning

confidence: 99%

Practice Guidelines for the Management of Patients with Histoplasmosis

Wheat

Sarosi

McKinsey

et al. 2000

Clinical Infectious Diseases

346

196

View full text Add to dashboard Cite

show abstract

“…After treatment completion, patients should be monitored for 1 to 2 years to capture relapsed disease (10-20% of cases). 75…”

Section: Chronic Pulmonary Histoplasmosismentioning

confidence: 99%

Current Concepts in the Epidemiology, Diagnosis, and Management of Histoplasmosis Syndromes

Azar

Loyd

Relich

et al. 2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Histoplasmosis is a global disease endemic to regions of all six inhabited continents. The areas of highest endemicity lie within the Mississippi and Ohio River Valleys of North America and parts of Central and South America. As a result of climate change and anthropogenic land utilization, the conditions suitable for Histoplasma capsulatum are changing, leading to a corresponding change in epidemiology. The clinical manifestations of histoplasmosis are protean, variably resembling other common conditions such as community-acquired pneumonia, tuberculosis, sarcoidosis, Crohn's disease, or malignancy. Making a successful diagnosis is contingent on a thorough understanding of epidemiology, common clinical presentations, and best testing practices for histoplasmosis. While most subclinical or self-limited diseases do not require treatment in immunocompetent patients, all immunocompromised patients and those with progressive disseminated disease or chronic pulmonary disease should be treated. Liposomal amphotericin B is the preferred agent for severe or disseminated disease, while itraconazole is adequate for milder cases and “step-down” therapy following response to amphotericin B. In this review, we discuss the current evidence-based approaches to the epidemiology, diagnosis, and management of histoplasmosis.

show abstract

“…After treatment completion, patients should be monitored for 1 to 2 years to capture relapsed disease (10-20% of the cases). 46 Progressive Disseminated Histoplasmosis…”

Section: Managementmentioning

confidence: 99%

Endemic Fungi Presenting as Community-Acquired Pneumonia: A Review

Azar

Malo

Hage

2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

AbstractIn endemic areas, dimorphic fungal infections due to Histoplasma capsulatum, Blastomyces dermatitidis, and Coccidioides posadasii/immitis account for up to 30% of cases of community-acquired pneumonia. Because respiratory manifestations are often indistinguishable from common bacterial causes of pneumonia, the diagnosis of pulmonary histoplasmosis, blastomycosis, and coccidioidomycosis is often delayed and associated with antibiotics overuse. In addition to being highly endemic to certain regions of North America, dimorphic fungi have global significance due to established areas of endemicity in all six inhabited continents, an increasingly interconnected world of travelers and transported goods, and a changing epidemiology as a result of global heating and anthropomorphic land utilization. In this review, we discuss the epidemiology, pathogenesis, clinical presentation, diagnostic modalities, and treatment strategies for histoplasmosis, blastomycosis, and coccidioidomycosis.

show abstract

Follow-up of Patients with Chronic Pulmonary Histoplasmosis Treated with Amphotericin B

Cited by 23 publications

References 7 publications

Practice Guidelines for the Management of Patients with Histoplasmosis

Practice Guidelines for the Management of Patients with Histoplasmosis

Current Concepts in the Epidemiology, Diagnosis, and Management of Histoplasmosis Syndromes

Endemic Fungi Presenting as Community-Acquired Pneumonia: A Review

Contact Info

Product

Resources

About